Leathanach 1 ó 27 torthaí
BACKGROUND OF THE INVENTION
Treatment of human cancer is an area of clinical medicine which remains fraught with complications and which often presents an array of suboptimal treatment choices. For example, prostate cancer, which is the most common cancer in men and the second leading cause of
FIELD OF THE INVENTION
The present invention relates generally to sesquiterpene derivatives, and more specifically to deoxyelephantopin derivatives.
BACKGROUND OF THE INVENTION
The identification and validation of the potential benefits of phytocompounds with low toxicity, but effective for cancer
This invention pertains to sesquiterpene lactones and sesquiterpene lactone-containing plant extracts and preparations for pharmaceutical uses, particularly the use of sesquiterpene lactones for the treatment of severe inflammatory disorders, for example, sepsis, septic shock, or septicemia.
A large
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
BACKGROUND OF THE INVENTION
The incidence of malignant glioma is approximately 12,000 new cases per year. These tumors represent the second leading cause of cancer mortality in people under the age of 35 and the fourth leading cause in
FIELD OF THE INVENTION
The present invention relates to the inhibition or killing of cancer cells. More particularly, the present invention relates to the systemic and topical treatments of cancer cells with sesquiterpene compounds.
BACKGROUND OF THE INVENTION
Artemisinin (Qinghaosu) and its analogs
FIELD OF THE INVENTION
This invention relates to a method for inhibition of cancer cells, comprising administrating an effective amount of formula I (Sesquiterpene lactones, antrocin) or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, wherein the
BACKGROUND OF THE INVENTION
Technical Field
The present invention belongs to the field of drug technology, specifically relates to the uses of sesquiterpene lactone compounds as the effective components or pharmaceutical composition in preparing drugs, especially the uses in preparing the drugs to
BACKGROUND OF THE INVENTION
1. Field of Invention
The present invention relates to novel sesquiterpene derivatives as a progesterone receptor binding inhibitor or salts thereof and use of these compounds as pharmaceuticals.
2. Background Art
Surgical endocrinotherapies for breast cancer include
INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 3, 2017, is named P12589-05_ST25.txt and
BACKGROUND OF THE INVENTION
Development of safe and effective agents for reducing the risk of cancer and other chronic diseases is a high priority of contemporary medicine. Implementation of strategies for chemoprevention/chemoprotection is beset with many problems.
In the economically developed
FIELD OF THE INVENTION
The present invention relates to monoterpene or sesquiterpene compositions. In particular, the present invention relates to using monoterpenes (such as (S)-perillyl alcohol) or sesquiterpenes having a purity greater than about 98.5% (w/w) to treat nervous system
FIELD OF THE INVENTION
The present invention relates to monoterpene or sesquiterpene compositions. In particular, the present invention relates to using monoterpenes (such as (S)-perillyl alcohol) or sesquiterpenes having a purity greater than about 98.5% (w/w) to treat nervous system
FIELD OF THE INVENTION
The present invention relates to monoterpene or sesquiterpene compositions. In particular, the present invention relates to using monoterpenes (such as (S)-perillyl alcohol) or sesquiterpenes having a purity greater than about 98.5% (w/w) to treat nervous system
FIELD OF THE INVENTION
The present invention relates to monoterpene or sesquiterpene compositions. In particular, the present invention relates to using monoterpenes (such as (S)-perillyl alcohol) or sesquiterpenes having a purity greater than about 98.5% (w/w) to treat nervous system
FIELD OF THE INVENTION
The present invention relates to monoterpene or sesquiterpene compositions. In particular, the present invention relates to using monoterpenes (such as (S)-perillyl alcohol) or sesquiterpenes having a purity greater than about 98.5% (w/w) to treat nervous system